Alembic Pharmaceuticals Limited has notified the Bombay Stock Exchange (BSE) and National Stock Exchange of India Limited (NSE) that a Meeting of the Board of Directors will be held on Tuesday, 4th August, 2026. The primary agenda of this meeting is to consider and approve the Unaudited Financial Results of the Company for the quarter ended 30th June, 2026.
Pursuant to the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company was closed from 1st July, 2026. The trading window will reopen 48 hours after the declaration of the financial results.
The disclosure is signed by G. Krishnan, Chief Financial Officer of Alembic Pharmaceuticals Limited, with digital signature verification showing GANESAN KRISHNAN as the signatory with timestamp 2026.07.24 17:34:15 +05'30'.
Financial Impact
Financial results for Q1 FY27 (quarter ended June 30, 2026) are pending board approval. Specific financial figures or impact not quantified in this disclosure.